NASDAQ:CGON CG Oncology Q2 2026 Earnings Results & Report $62.27 -0.13 (-0.21%) As of 09:50 AM Eastern This is a fair market value price provided by Massive. Learn more. CG Oncology missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.90 versus the -$0.6642 consensus estimate, while revenue of $1.16 million topped the $0.36 million estimate by $0.80 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call8:30 AM ET CG Oncology EPS ResultsActual EPS-$0.90Consensus EPS -$0.6642Beat/MissMissed by -$0.2359One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCG Oncology Revenue ResultsActual Revenue$1.16 millionExpected Revenue$0.36 millionBeat/MissBeat by +$796.00 thousandYoY Revenue GrowthN/AUpcoming EarningsCG Oncology's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CG Oncology Q2 2026 Earnings FAQ Did CG Oncology beat earnings estimates for Q2 2026? CG Oncology (NASDAQ:CGON) reported earnings of -$0.90 per share for Q2 2026, missing the consensus estimate of -$0.6642. The report was announced on Thursday, August 6, 2026. What was CG Oncology's revenue for Q2 2026? CG Oncology reported revenue of $1.16 million for Q2 2026, against a consensus estimate of $0.36 million. When is CG Oncology's next earnings date? CG Oncology's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for CG Oncology on the company's earnings history page. CG Oncology Earnings HeadlinesCG Oncology, Inc. Appoints Isabel Kalofonos as Chief Commercial OfficerOctober 13 at 10:31 PM | marketscreener.comMCG Oncology Inc CGONOctober 13 at 10:31 PM | morningstar.comMTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 15 at 1:00 AM | Porter & Company (Ad)How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer LaunchOctober 13 at 10:31 PM | finance.yahoo.comCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerOctober 13 at 8:00 AM | globenewswire.comCG Oncology (NASDAQ:CGON) and Myriad Genetics (NASDAQ:MYGN) Head-To-Head ReviewOctober 13 at 4:45 AM | americanbankingnews.comSee More CG Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email. Email Address About CG OncologyCG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer and other cancers of the urinary tract. The company’s research centers on cancer-directed immunotherapies designed to stimulate the immune system and target tumor cells. Its lead product candidate is cretostimogene grenadenorepvec, an intravesical oncolytic adenovirus being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC). The therapy is designed to be delivered directly into the bladder, where it may selectively infect tumor cells and activate an immune response against cancer. CG Oncology has evaluated cretostimogene in clinical studies involving patients with NMIBC, including individuals whose disease has not responded adequately to Bacillus Calmette-Guérin (BCG), a standard bladder cancer treatment. The company’s development efforts have included studies of different NMIBC patient populations and treatment settings. CG Oncology is headquartered in California and has focused its operations primarily on advancing its oncology pipeline through clinical development.View CG Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
